Cefaclor NDC 0093-1087

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-1087Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-1087Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-1087-01	00093108701	100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0093-1087-01)Marketed from Sep 26, 2002

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cefaclor
Generic name (nonproprietary): cefaclor
Active ingredients: Cefaclor — 500 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 065058
Marketing start: Sep 26, 2002
Listing expires: Dec 31, 2026
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 0093-1087_61ec00e0-d37d-4aa4-8f50-031ee7a37eccSPL ID 61ec00e0-d37d-4aa4-8f50-031ee7a37eccSPL set ID 0878bdc2-0410-4938-9890-96523aa81c2fRxCUI 309043UNII 69K7K19H4L
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093108701 followed by a unit qualifier and the quantity

Package 00093-1087-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2019.

Indications (excerpt from the label)

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indic…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)